Evidence map›Paper›PMID 42316565›Full record

ArticleCurrent medical imaging2026

The Prognostic and Mutational Characteristics of Multiple Early-stage Lung Cancers Manifesting as Subsolid Nodules.

Bin Wang, Jiabi Zhao, Xiwen Sun, Yangyang Sun

Abstract read
In one paragraph

Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bin WangDepartment of Radiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0009-0001-2663-6125
Jiabi ZhaoDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0009-0000-2377-9932
Xiwen SunDepartment of Radiology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0000-0002-0006-0930
Yangyang SunDepartment of Radiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0000-0001-9281-1430

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION/

objectiveTo explore the prognostic and EGFR mutational characteristics of patients with multiple lung subsolid nodules (SSNs) after surgical resection.

methodsA retrospective analysis was performed on 250 patients with pathologically confirmed T1aN0M0 lung cancer, who were divided into single SSN (n = 126), multiple SSNs (n = 42), and single solid nodule (n = 82) groups. All patients underwent a single surgical resection and were followed up to assess recurrence-free survival (RFS) and overall survival (OS). EGFR mutation testing was performed in 131 patients.

resultsThe 5-year OS rates were 100% (single SSN group), 95.2% (multiple SSNs group), and 89.0% (solid nodule group) (single vs. multiple SSNs, P < 0.05; multiple SSNs vs. solid nodules, P = 0.226). The 5-year RFS rates were 99.2%, 88.1%, and 76.8%, respectively (single vs. multiple SSNs, P < 0.01; multiple SSNs vs. solid nodules, P = 0.111). EGFR mutation rates were 69.2%, 71.4%, and 42.1% in the three groups, respectively. DISCUSSION: Patients with multiple subsolid nodules on CT had a slightly worse prognosis than those with a single subsolid nodule. It may be necessary to reconsider the rationale for simply classifying all multiple subsolid nodules as multiple primary lung cancers (MPLC). The high EGFR mutation rate in the multiple subsolid nodule group suggests that targeted therapy may be a potential treatment option for patients with multiple subsolid lesions.

conclusionCT-detected multiple subsolid nodules are associated with a slightly poorer prognosis than single subsolid nodules, resist simplistic classification as multiple primary lung cancers, and exhibit a high EGFR mutation rate that supports targeted therapy as a treatment option.

Indexed as

Lung NeoplasmsMultiple Pulmonary NodulesAgedErbB ReceptorsFemaleHumansMaleMiddle AgedMutationNeoplasm StagingPrognosisRetrospective StudiesEGFR protein, humanErbB ReceptorsComputed tomographyEpidermal growth factor receptorLung neoplasmsOverall survivalRecurrence-free survivalTyrosine kinase inhibitors

Identifiers

PMID42316565
PMCPMC13613315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.